Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine zipper protein 2 (LUZP2)
- Target
- LUZP2
- Molecular classification
- Transcription factor (leucine zipper family)
01
Overview
Leucine zipper protein 2 (LUZP2) is a conserved, predominantly brain-expressed transcription factor featuring a leucine zipper motif that facilitates protein-protein interactions and regulates gene expression. The gene is located on chromosome 11p14.3 and is expressed at higher levels in the cerebral cortex, thalamus, and hypothalamus. LUZP2 is downregulated in higher-grade gliomas and its genetic variants have been implicated in higher risk for Alzheimer’s disease and poorer cognitive function. While not drug-targeted, LUZP2 may have biomarker potential in certain neurological diseases, and its exact biological role appears related to neurodevelopment and disease progression in the central nervous system[1][2][4].
- Other names
- LUZP2KFSP2566PRO6246UNQ2566/PRO6246leucine zipper protein 2
02
Mechanism of action
Not applicable; no drugs are known to target this molecule directly
03
Biological functions
Protein-protein interactions (mediated via leucine zipper motif)Regulation of gene expression (as a transcription factor)Potential role in neural development and nervous system extracellular matrix
04
Disease associations
Low-grade glioma: LUZP2 downregulation correlates with higher tumor grade and worse survivalNeurodegenerative disease: Genetic variants linked to increased Alzheimer’s risk and brain atrophyWilms tumor-aniridia-genitourinary anomalies-mental retardation (WAGR) syndrome: Gene deletions observed in some patientsOther: Associated with cognitive performance in the elderly
05
Safety considerations
No specific safety concerns are documented for targeting LUZP2, as it is not currently a therapeutic target
06
Biomarkers
LUZP2 expression levels may serve as a biomarker in low-grade glioma prognosisLUZP2 variants associated with plasma neurofilament light levels and brain atrophy
Beyond the preview
Go deeper on Leucine zipper protein 2 (LUZP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine zipper protein 2 (LUZP2).